ERα is a critical factor in the development and progression of estrogen-related cancers, particularly breast cancer. About 70% of breast cancers are ERα-positive, meaning they express this receptor and are likely to respond to hormonal therapies such as tamoxifen or aromatase inhibitors. The status of ERα in a tumor can guide oncologists in devising effective treatment plans.
